Nodus Oncology Secures £2.4m ($2.9m) Investment Nodus Oncology Secures £2.4m ($2.9m) Investment KHAN Technology Transfer Fund I (KHAN-I) have invested alongside existing investor Cumulus Oncology Bert Klebl, Managing Director of KHAN-I will join...

Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme Acquisition enables Nodus Oncology to continue building its portfolio of first and best-in-class molecules...

Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response...